NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for androgen-independent


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Findings from K.V. Thomas and co-authors broaden understanding of science and technology
2009 NOV 27 -- "Produced water from offshore oil production platforms represents the largest direct discharge of effluent into the offshore environment Produced water effluents contain a complex mixture of substances which are known to bind to the estrogen......
Subject: Science and Technology
Price: $3.00
*
GTx, Inc. Reports Third Quarter 2009 Corporate Results
2009 NOV 23 -- GTx, Inc. (Nasdaq: GTXI) reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9......
Subject: GTx, Inc.
Price: $3.00
*
Nagoya City University reports research in prostate cancer animal studies
2009 NOV 23 -- Fresh data on prostate cancer are presented in the report 'Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor.' "The soybean-derived......
Subject: Prostate Cancer Animal Studies
Price: $3.00
*
New endocrinology research from University of Edinburgh described
2009 NOV 18 -- "Common male reproductive abnormalities including cryptorchidism, hypospadias, and low sperm counts may comprise a testicular dysgenesis syndrome (TDS), resulting from fetal testis dysfunction during a critical developmental period involving......
Subject: Endocrinology
Price: $3.00
*
New prostate cancer study findings recently were published by researchers at Loyola University Chicago
2009 NOV 23 -- According to a study from the United States, "Androgen deprivation therapy for prostate cancer is associated with osteoporosis and increased fracture risk. Previous studies of zoledronic acid demonstrated bone loss prevention in patients......
Subject: Prostate Cancer
Price: $3.00
*
New prostate cancer study findings recently were published by S.C. Cooper and co-researchers
2009 NOV 23 -- "Oesophageal adenocarcinoma (OAC) is more common in men. Androgens may therefore contribute to the pathogenesis of OAC," scientists writing in the journal Cancer Causes & Control report.    "Prostate cancer (PC), an androgen......
Subject: Prostate Cancer
Price: $3.00
*
New science study findings have been reported from Hallym University
2009 NOV 26 -- According to recent research from South Korea, "Piceatannol (trans-3,4,30,50-tetrahydroxystilbene) is a polyphenol that is found in grapes, red wine, Rheum undulatum, and the seeds of Euphorbia lagascae. It has been previously reported that......
Subject: Science
Price: $3.00
*
Reports from University of Washington, Department of Urology add new data to research in prostate cancer therapy
2009 NOV 23 -- Current study results from the report, 'HE3235 inhibits growth of castration-resistant prostate cancer,' have been published. According to recent research from the United States, "Treatments for advanced prostate cancer (CaP) typically involve......
Subject: Prostate Cancer Therapy
Price: $3.00
*
Research findings from Shanghai Jiao Tong University update understanding of urology
2009 NOV 23 -- According to recent research from Shanghai, People's Republic of China, "We developed an organotypic genital tubercle culture system in vitro and used it to investigate the direct effects of the hyperestrogenic state on fetal mouse penile and......
Subject: Urology
Price: $3.00
*
Research from Oregon Health & Science University in the area of prostate cancer published
2009 NOV 23 -- According to recent research from the United States, "High consumption of cruciferous vegetables is associated with a reduced risk of prostate cancer in epidemiological studies. There is preliminary evidence that sulforaphane, derived from......
Subject: Prostate Cancer
Price: $3.00
*
Research from R.A. Giron and co-researchers in the area of cervical cancer published
2009 NOV 23 -- According to a study from Mexico, "Dehydroepiandrosterone (DHEA) has a protective role against epithelial-derived carcinomas; however, the mechanisms remain unknown. We determined the effect of DHEA on cell proliferation, the cell cycle and cell......
Subject: Cervical Cancer
Price: $3.00
*
Researchers at Ewha Womans University have published new data on molecular research
2009 NOV 24 -- "The modulating effect of IGF-I on the regulation of AR gene expression and activation in skeletal muscle cells remains poorly understood. In this study, the effects of IGF-I treatment on AR induction and activation in the absence of AR ligands......
Subject: Molecular Research
Price: $3.00
*
Researchers at McMaster University target prostate cancer
2009 NOV 23 -- According to a study from Hamilton, Canada, "A 49-year-old patient with high-risk prostate cancer presented to a specialist. He was treated with neoadjuvant hormonal therapy for 6 months, followed by conformal radiotherapy."   ......
Subject: Prostate Cancer
Price: $3.00
*
Researchers from St. Vincent's Hospital publish new studies and findings in the area of transdermal delivery
2009 NOV 23 -- "Fat mass is increased in hypogonadal men and the changes are reversed by testosterone replacement. Testosterone administration enhances whole body fat oxidation (Fox)," researchers in Australia report.    "Fat is oxidized in the......
Subject: Transdermal Delivery
Price: $3.00
*
Studies from Boston University, Medical Department provide new data on prostate cancer
2009 NOV 23 -- According to recent research from the United States, "The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered......
Subject: Prostate Cancer
Price: $3.00
*
Studies from Massachusetts General Hospital, Division of Hematology-Oncology yield new information about prostate cancer therapy
2009 NOV 23 -- Investigators publish new data in the report 'Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.' According to recent research published in the Journal of General Internal Medicine,......
Subject: Prostate Cancer Therapy
Price: $3.00
*
Study results from Tuskegee University, Medical Department update understanding of reproduction
2009 NOV 24 -- "This study tested the hypothesis that the estrogen receptor (ESR) pathway, androgen receptor (AR) pathway, or both mediate estrogen-induced developmental penile disorders. Rat pups received diethylstilbestrol (DES), with or without the ESR......
Subject: Reproduction
Price: $3.00
*
Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer
2009 NOV 23 -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration......
Subject: Tokai Pharmaceuticals
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login